The clinical and phenotypic spectrum of PTEN hamartoma tumor syndrome: a retrospective cohort study
Einat Ritter, Aasem Abu Shtaya, Revital Kariv, Sari Lieberman, Elizabeth Half, Maria Postnikov, Guy Rosner, Hana Strul, Nathan Gluck, Lior Katz, Ephrat Levy-Lahad, Dalit May, Ido Laish, Yael Goldberg, Elez Vainer, Zohar Levi, Maya Aharoni Golan · 2026
Read The clinical and phenotypic spectrum of PTEN hamartoma tumor syndrome: a retrospective cohort study by Einat Ritter, Aasem Abu Shtaya, Revital Kariv, Sari Lieberman, Elizabeth Half, Maria Postnikov, Guy Rosner, Hana Strul, Nathan Gluck, Lior Katz, Ephrat Levy-Lahad, Dalit May, Ido Laish, Yael Goldberg, Elez Vainer, Zohar Levi, Maya Aharoni Golan (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13585824.txt.
Introduction
Einat Ritter and co-authors describe the range of illness seen in a rare inherited condition called PTEN hamartoma tumor syndrome. People with the condition grow benign lumps in the gut and face a high lifetime risk of cancer. The team reviewed adults followed at special high-risk clinics to map the condition's full picture.
The study covered sixty-two adults, most of them men, with a median age near forty. A harmful change in the PTEN gene was found in about four out of five. Growths in the colon appeared in forty patients. Cancer had occurred in sixty-one percent, most often in the breast and thyroid. Three people had rare soft tissue tumors. The authors stress that the condition's reach is broad. They advise doctors to consider hidden gene changes when tests on blood come back negative but suspicion stays high.
Catalog record
| CREATOR | Einat Ritter, Aasem Abu Shtaya, Revital Kariv, Sari Lieberman, Elizabeth Half, Maria Postnikov, Guy Rosner, Hana Strul, Nathan Gluck, Lior Katz, Ephrat Levy-Lahad, Dalit May, Ido Laish, Yael Goldberg, Elez Vainer, Zohar Levi, Maya Aharoni Golan |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 33 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
The clinical and phenotypic spectrum of PTEN hamartoma tumor syndrome: a retrospective cohort study Authors: Einat Ritter, Aasem Abu Shtaya, Revital Kariv, Sari Lieberman, Elizabeth Half, Maria Postnikov, Guy Rosner, Hana Strul, Nathan Gluck, Lior Katz, Ephrat Levy-Lahad, Dalit May, Ido Laish, Yael Goldberg, Elez Vainer, Zohar Levi, Maya Aharoni Golan Published: 2026 ABSTRACT PTEN Hamartoma Tumor Syndrome (PHTS) is a rare condition characterized by a complex phenotype including gastrointestinal hamartomas and increased lifetime malignancy risk. To characterize the clinical phenotype, genetic landscape, and spectrum of malignancies within a large cohort of adult PHTS carriers. A retrospective cohort study of adult patients (≥ 18 years) followed at specialized high-risk clinics who met PHTS diagnostic criteria based on either: (1) identification of a germline PTEN pathogenic/likely pathogenic variant, or (2) fulfillment of clinical criteria according to National Comprehensive Cancer Network (NCCN) guidelines. A total of 62 individuals were included (62.9% male; median age at inclusion 39.5, IQR, 28–52). All fulfilled diagnostic criteria for PHTS. PTEN pathogenic or likely pathogenic variant were identified in 50 individuals (80.6%). Colonic polyps were present in 40 patients. Malignancies were reported in 61% (n = 38), most frequently breast (n=13) and thyroid (n=7). Three individuals (4.8%) had rare soft tissue tumors: one with a desmoid tumor at age 18, one with concurrent axillary osteosarcoma and bilateral chest liposarcoma, and one with a skull-base sarcoma. Macrocephaly was observed in 33.8% (n = 21), and developmental delay, including autism spectrum disorder, in 8 patients (12.9%). One case of PTEN mosaicism was identified through tumor sequencing after negative blood genetic testing. Five individuals (8%) were treated with Sirolimus. This large cohort highlights the broad clinical spectrum and substantial cancer burden in PHTS, including rare soft tissue tumors. Constitutional mosaicism should be considered when clinical suspicion persists despite negative germline testing.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1007/s10689-026-00604-w. Introduction The PTEN hamartoma tumor syndrome (PHTS) encompasses a spectrum of rare disorders caused by a germline pathogenic/likely pathogenic variant (P/LP variant) within the phosphate and tensin homolog (PTEN) gene (MIM 601728). PTEN, located on chromosome 10, functions as a tumor suppressor gene regulating cellular growth. Beyond its role in suppressing tumorigenesis, PTEN is crucial for normal embryonic development, particularly within the central nervous system where it orchestrates neural stem cell proliferation, cell migration, and synaptic plasticity. A pathogenic or likely pathogenic germline variant leads to dysregulation of the mTOR pathway, which normally promotes cell growth, survival, and proliferation, thereby enhancing cell proliferation and inhibiting apoptosis [1]. In addition to its role in tumorigenesis, PTEN loss has been increasingly linked to immune dysregulation and chronic inflammatory processes. This is mediated through aberrant activation of the PI3K–AKT–mTOR signaling pathway, which influences cytokine production, immune cell differentiation and the tumor microenvironment [2]. PHTS encompasses several historical clinical subtypes, such as Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome, which are now recognized not as distinct syndromes, but as a single disease entity with age-dependent phenotypic presentations that can occur within the same family [3, 4]. The prevalence of PHTS is estimated at 1 in 100,000 to 200,000 individuals. While childhood presentations are typically dominated by macrocephaly, autism, developmental delay, vascular malformations, or benign intestinal polyposis, cancer-related features become prominent in adulthood. Adults with PHTS are highly predisposed to both benign and malignant tumors, most notably breast, thyroid, and endometrial cancers, as well as renal cell carcinoma,colorectal cancer and melanoma. A pathogenic or likely pathogenic germline variant in PTEN drives these diverse manifestations across the lifespan [5–7]. PHTS diagnosis is based upon diagnostic criteria, including the most recent National Comprehensive Cancer Network (NCCN) guidelines that recommend relying on a combination of major and minor clinical criteria or the detection of a PTEN pathogenic or likely pathogenic variant for definitive diagnosis [8]. Despite established diagnostic criteria, the wide phenotypic variability of PHTS poses significant challenges in identifying affected individuals. While some patients present with only mild or benign manifestations, others experience developmental delays, severe clinical symptoms, or life-threatening malignancies. Furthermore, uncommon or atypical features remain poorly characterized, complicating both diagnosis and counseling [9]. The aim of this study is to describe the spectrum of the clinical, endoscopic, and genetic characteristics of patients with PHTS with an emphasis on rare clinical findings and diagnostic approach. Methods This retrospective cohort study included adult patients (age ≥18 years) who were diagnosed with PHTSbased on either: [1] identification of a germline PTEN pathogenic/likely pathogenic variant, or [2] fulfillment of clinical criteria according to National Comprehensive Cancer Network (NCCN) guidelines. A clinical diagnosis was established based on the presence of a combinations of major and minor criteria.[10] Patients were followed in six tertiary academic centers. Age at diagnosis was defined as the chronological age at which the patient was first clinically or genetically diagnosed with PHTS. Age at inclusion was defined as the age of the patient at the time of study initiation and cohort data collection. Most patients carry a known PTEN P/LP variant, identified through Sanger sequencing or multigene next-generation sequencing (NGS) panels. A comprehensive chart review was performed extracting demographic, medical and genetic data, including age, biologic sex, follow-up duration, PTEN variant status and type, phenotypic features, family history of PHTS, occurrence of malignant and pre-malignant lesions and pharmacologic therapies received. Upper and lower gastrointestinal (GI) endoscopy reports were reviewed for inflammatory findings, polyp burden and histology. PTEN pathogenic variants were documented by the precise Human Genome Variation Society nomenclature (HGVS) (Transcript NM_314.8). Variants were classified according to the ClinGen PTEN Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines. The study was approved by the Institutional review board in each medical center. Informed consent was waived. Statistical methods and data analysis Data were summarized using standard descriptive statistics. Categorical variables are presented as frequencies and percentages, and continuous variables are reported as medians with IQR. Results Clinical characteristics Sixty-two patients were included in the study; 37.1% were female, the median age at diagnosis was 30 years (IQR 19–46), median follow-up time was 5.5 years (IQR 3–15), and 80% had at least one first-degree relative with PHTS diagnosis. The most common benign manifestations included colonic polyps (40 patients), macrocephaly (33.8%), benign thyroid disease and mucocutaneous lesions (29% and 26% respectively). Among the 12 patients who did not carry pathogenic/likely pathogenic variant in PTEN gene, the diagnosis was based on a combination of major and minor criteria according to NCCN guidelines[10]. Demographic characteristics and clinical findings are depicted in Table 1 and Supplementary Table 1.Table 1Demographic and clinical characteristics of patients with PHTSCharacteristicsStudy Cohort (n=62) Female sex, n (%)23 (37.1) Age at data collection years, median, (IQR)39.5 (28–52) Age at diagnosis, years median, (IQR)30 (19–46) Median follow-up time, years median, (IQR)5.5 (3–15) First degree family member with PHTS, n (%)50 (80.6)Ethnicity Jewish, n (%)55 (88.7) Arab, n (%)7 (11.2)PHTS phenotype Thyroid gland manifestations Benign, n (%)†18 (29.0) Thyroidectomy, n (%)6 (9.6)Mucocutaneous manifestations µ Oral mucosa lesions, n (%)15 (24.1) Pigmented macules on penis, n (%)11 (17.7) Other, n (%)23 (37.1) Macrocephaly, n (%)21 (33.8) Developmental delay, n (%)8 (12.9) Vascular abnormalities, n (%) ¥5 (8.1) Benign urologic manifestations, n (%) £8 (12.9) Benign gynecologic manifestations, n (%) €5 (8.1)mTOR Treatment, n (%)PTEN Genotype5 (12.9) ACMG based Classification Pathogenic/likely pathogenic variant,